C4 Therapeutics, Inc. (CCCC) shareholders
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3016% above fair value
$2.77−0.12 (-4.15%)
Close on Nov 12, 2026Market cap $340.78MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
95.6%
118M of 123M shares
Institutional holders
148
52 new, 27 sold out
Net institutional buying
33M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $22.20K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Sirenia Capital Management LP Joint filing with Alex Silverstein (9.90%) | 23,505,000 | 9.90% | 13G (passive) | Mar 31, 2026 |
| Steven A. Cohen Joint filing with Point72 Asset Management, L.P. (9.90%), Point72 Capital Advisors, Inc. (9.90%) | 22,647,647 | 9.90% | 13G (passive) | Oct 17, 2025 |
| Weston Nichols Joint filing with Lynx1 Capital Management LP (9.99%) | 15,423,691 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 11,383,696 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Soleus Capital, LLC Joint filing with Soleus Capital Master Fund, L.P. (9.99%), Soleus Capital Group, LLC (9.99%) and 6 more | 10,361,860 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Morgan Stanley Joint filing with Morgan Stanley Capital Services LLC (7.90%) | 8,862,002 | 8.00% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 7,678,906 | 6.90% | 13G (passive) | Jun 30, 2026 |
| Squadron Master Fund LP Joint filing with Squadron Capital Management LLC (6.90%), Matthew Sesterhenn (6.90%) and 1 more | 7,600,000 | 6.90% | 13G (passive) amendment | Jun 30, 2026 |
| Lynx1 Capital Management LP Joint filing with Weston Nichols (7.30%) | 7,098,133 | 7.30% | 13G (passive) amendment | Dec 31, 2025 |
| BCLS II Equity Opportunities, LP | 6,060,000 | 6.25% | 13G (passive) | Oct 17, 2025 |
| Betta Investment (Hong Kong) Limited Joint filing with Betta Pharmaceuticals Co., Ltd. (8.10%) | 5,567,928 | 8.10% | 13G (passive) | Jan 4, 2024 |
| Matthew Sesterhenn Joint filing with Squadron Master Fund LP (5.00%), Squadron Capital Management LLC (5.00%) and 1 more | 5,550,000 | 5.00% | 13G (passive) | May 12, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CCCC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Morgan Stanley | 8,867,338 | 7.21% | $41.41M | −205,062 | 0.00% |
| Ra Capital Management, L.P. | 8,000,000 | 6.50% | $37.36M | – | 0.32% |
| BlackRock, Inc. | 7,896,718 | 6.42% | $36.88M | +5,848,192 | 0.00% |
| Lynx1 Capital Management LP | 7,326,691 | 5.96% | $34.22M | +327,789 | 3.95% |
| Squadron Capital Management LLC | 7,200,000 | 5.85% | $33.62M | +4,950,000 | 10.43% |
| Bain Capital Life Sciences Investors, LLC | 7,171,910 | 5.83% | $33.49M | – | 1.99% |
| JPMorgan Chase & Co | 4,747,424 | 3.86% | $20.65M | +1,524,370 | 0.00% |
| Vanguard Capital Management LLC | 4,417,731 | 3.59% | $20.63M | +555,879 | 0.00% |
| Citadel Advisors LLC | 4,187,580 | 3.40% | $19.56M | +1,676,565 | 0.00% |
| Goldman Sachs Group Inc | 3,530,991 | 2.87% | $16.49M | +1,143,613 | 0.00% |
| Wasatch Advisors LP | 3,522,644 | 2.86% | $16.45M | +560,883 | 0.11% |
| Two Sigma Investments, LP | 3,469,707 | 2.82% | $16.20M | +434,073 | 0.01% |
| Soleus Capital Management, L.P. | 3,377,981 | 2.75% | $15.78M | −425,961 | 0.54% |
| Silverarc Capital Management, LLC | 3,032,060 | 2.46% | $14.16M | +1,120,275 | 1.47% |
| Bank Of America Corp /De/ | 2,656,359 | 2.16% | $12.41M | +297,118 | 0.00% |
| Geode Capital Management, LLC | 2,522,163 | 2.05% | $11.78M | +1,571,120 | 0.00% |
| Ikarian Capital, LLC | 2,433,000 | 1.98% | $11.36M | New | 1.22% |
| State Street Corp | 2,115,621 | 1.72% | $9.88M | +1,732,648 | 0.00% |
| Acadian Asset Management LLC | 1,806,199 | 1.47% | $8.43M | −84,715 | 0.01% |
| Candriam S.C.A. | 1,796,937 | 1.46% | $8.38M | New | 0.04% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 148 | 118M | 95.6% | 52 / 53 | 28 / 27 | 41M | 9M |
| Q1 2026 | 123 | 85M | 69.0% | 34 / 41 | 32 / 11 | 24M | 14M |
| Q4 2025 | 101 | 80M | 64.9% | 24 / 44 | 20 / 16 | 38M | 11M |
| Q3 2025 | 97 | 53M | 42.7% | 21 / 27 | 37 / 26 | 6M | 8M |
| Q2 2025 | 102 | 55M | 44.6% | 26 / 32 | 32 / 39 | 7M | 16M |
| Q1 2025 | 115 | 64M | 52.1% | 27 / 40 | 28 / 23 | 8M | 8M |
| Q4 2024 | 113 | 64M | 52.3% | 25 / 37 | 34 / 29 | 9M | 9M |
| Q3 2024 | 118 | 64M | 52.2% | 31 / 37 | 30 / 26 | 17M | 9M |
| Q2 2024 | 115 | 61M | 49.5% | 35 / 31 | 35 / 25 | 15M | 14M |
| Q1 2024 | 106 | 59M | 48.2% | 39 / 29 | 27 / 25 | 23M | 11M |
| Q4 2023 | 92 | 47M | 38.4% | 31 / 29 | 23 / 22 | 22M | 9M |
| Q3 2023 | 83 | 35M | 28.1% | 7 / 30 | 32 / 23 | 6M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
96 funds held CCCC in Q2 2026, 59% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CCCC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,264,924 | 2.65% | $15.25M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,595,893 | 2.11% | $12.12M | 0.01% | Jun 30, 2026 |
| Wasatch Ultra Growth Fund | 2,503,777 | 2.04% | $11.69M | 2.53% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,110,012 | 0.90% | $3.86M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,047,349 | 0.85% | $4.89M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 931,903 | 0.76% | $4.35M | 0.03% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 780,673 | 0.63% | $3.65M | 0.06% | Jun 30, 2026 |
| Wasatch Micro Cap Fund | 761,872 | 0.62% | $3.56M | 0.53% | Jun 30, 2026 |
| iShares Biotechnology ETF | 707,427 | 0.58% | $3.30M | 0.04% | Jun 30, 2026 |
| JNL Multi-Manager Small Cap Value Fund | 633,783 | 0.52% | $2.96M | 0.15% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 415,948 | 0.34% | $1.82M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 377,039 | 0.31% | $1.65M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 340,711 | 0.28% | $1.59M | 0.10% | Jun 30, 2026 |
| Small Cap Value Fund | 307,074 | 0.25% | $1.43M | 0.21% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 246,397 | 0.20% | $857.46K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Andrew Hirsch | President & CEO, Director | 1,083,991 | 0.88% | Feb 18, 2026 |
| Kendra Adams | Chief Financial Officer | 385,098 | 0.31% | Sep 21, 2026 |
| Leonard Reyno | Chief Medical Officer | 372,406 | 0.30% | Jul 13, 2026 |
| Kelly Schick | Chief People Officer | 299,881 | 0.24% | Feb 18, 2026 |
| Mark Mossler | Chief Accounting Officer | 71,916 | 0.06% | Feb 18, 2026 |
| Paige Mahaney | Chief Scientific Officer | 336,910 | 0.27% | Feb 18, 2026 |
| Scott N. Boyle | Chief Business Officer | 306,070 | 0.25% | Feb 18, 2026 |
| Jolie Siegel | Chief Legal Officer | 107,939 | 0.09% | Feb 18, 2025 |
| Kenneth Carl Anderson | Director | 361,897 | 0.29% | Oct 2, 2026 |
| Donna Roy Grogan | Director | 79,471 | 0.06% | Oct 2, 2026 |
| Owen Hughes | Director | – | – | Jun 26, 2026 |
| Utpal Koppikar | Director | 5,667 | 0.00% | Jun 26, 2026 |
| Steven L. Hoerter | Director | – | – | Jun 26, 2026 |
| Laura Bessen | Director | – | – | Jun 26, 2026 |
| Ronald Harold Wilfred Cooper | Director | – | – | Jun 26, 2026 |
| Stephen Fawell | Director | – | – | Jun 26, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kenneth Carl Anderson Director | Oct 1, 2026 | Award | +3,662 | $3.14 | $11.50K | 75,612 |
| Donna Roy Grogan Director | Oct 1, 2026 | Award | +4,618 | $3.14 | $14.50K | 79,471 |
| Kendra Adams Chief Financial Officer | Sep 18, 2026 | Option exercise | +6,250 | – | – | 385,098 |
| Kendra Adams Chief Financial Officer | Sep 18, 2026 | Tax withholding | −2,775 | $3.39 | $9.41K | 382,323 |
| Leonard Reyno Chief Medical Officer | Jul 10, 2026 | Tax withholding | −7,397 | $4.06 | $30.03K | 372,406 |
| Leonard Reyno Chief Medical Officer | Jul 10, 2026 | Option exercise | +15,325 | – | – | 379,803 |
| Donna Roy Grogan Director | Jul 1, 2026 | Award | +3,341 | $4.34 | $14.50K | 74,853 |
| Kenneth Carl Anderson Director | Jul 1, 2026 | Award | +2,650 | $4.34 | $11.50K | 71,950 |
| Kenneth Carl Anderson Director | Jun 1, 2026 | Option exercise | +1,070 | $2.11 | $2.26K | 69,300 |
| Donna Roy Grogan Director | Apr 1, 2026 | Award | +5,370 | $2.70 | $14.50K | 71,512 |
| Kenneth Carl Anderson Director | Apr 1, 2026 | Award | +4,259 | $2.70 | $11.50K | 68,230 |
| Andrew Hirsch President & CEO, Director | Feb 15, 2026 | Option exercise | +20,400 | – | – | 1,083,991 |
| Andrew Hirsch President & CEO, Director | Feb 15, 2026 | Tax withholding | −9,057 | $1.89 | $17.12K | 1,074,934 |
| Mark Mossler Chief Accounting Officer | Feb 14, 2026 | Tax withholding | −3,268 | $1.89 | $6.18K | 71,916 |
| Mark Mossler Chief Accounting Officer | Feb 14, 2026 | Option exercise | +9,420 | – | – | 75,184 |
| Scott N. Boyle Chief Business Officer | Feb 14, 2026 | Option exercise | +20,950 | – | – | 306,070 |
| Scott N. Boyle Chief Business Officer | Feb 14, 2026 | Tax withholding | −7,269 | $1.89 | $13.74K | 298,801 |
| Paige Mahaney Chief Scientific Officer | Feb 14, 2026 | Tax withholding | −2,446 | $1.89 | $4.62K | 336,910 |
| Paige Mahaney Chief Scientific Officer | Feb 14, 2026 | Option exercise | +7,050 | – | – | 339,356 |
| Kendra Adams Chief Financial Officer | Feb 14, 2026 | Option exercise | +30,950 | – | – | 400,479 |
| Kendra Adams Chief Financial Officer | Feb 14, 2026 | Tax withholding | −15,381 | $1.89 | $29.07K | 385,098 |
| Kelly Schick Chief People Officer | Feb 14, 2026 | Tax withholding | −7,269 | $1.89 | $13.74K | 299,881 |
| Kelly Schick Chief People Officer | Feb 14, 2026 | Option exercise | +20,950 | – | – | 307,150 |
| Leonard Reyno Chief Medical Officer | Feb 14, 2026 | Option exercise | +30,950 | – | – | 396,382 |
| Leonard Reyno Chief Medical Officer | Feb 14, 2026 | Tax withholding | −16,579 | $1.89 | $31.33K | 379,803 |
| Andrew Hirsch President & CEO, Director | Feb 14, 2026 | Option exercise | +81,725 | – | – | 1,123,145 |
| Andrew Hirsch President & CEO, Director | Feb 14, 2026 | Tax withholding | −39,154 | $1.89 | $74.00K | 1,083,991 |
| Mark Mossler Chief Accounting Officer | Feb 13, 2026 | Award | +56,980 | – | – | 75,184 |
| Scott N. Boyle Chief Business Officer | Feb 13, 2026 | Tax withholding | −1,735 | $1.89 | $3.28K | 306,070 |
| Scott N. Boyle Chief Business Officer | Feb 13, 2026 | Option exercise | +5,000 | – | – | 307,805 |
| Scott N. Boyle Chief Business Officer | Feb 13, 2026 | Award | +200,000 | – | – | 307,805 |
| Paige Mahaney Chief Scientific Officer | Feb 13, 2026 | Award | +240,000 | – | – | 339,356 |
| Kendra Adams Chief Financial Officer | Feb 13, 2026 | Option exercise | +3,750 | – | – | 402,342 |
| Kendra Adams Chief Financial Officer | Feb 13, 2026 | Award | +240,000 | – | – | 402,342 |
| Kendra Adams Chief Financial Officer | Feb 13, 2026 | Tax withholding | −1,863 | $1.89 | $3.52K | 400,479 |
| Kelly Schick Chief People Officer | Feb 13, 2026 | Tax withholding | −1,735 | $1.89 | $3.28K | 307,150 |
| Kelly Schick Chief People Officer | Feb 13, 2026 | Option exercise | +5,000 | – | – | 308,885 |
| Kelly Schick Chief People Officer | Feb 13, 2026 | Award | +200,000 | – | – | 308,885 |
| Leonard Reyno Chief Medical Officer | Feb 13, 2026 | Award | +240,000 | – | – | 396,382 |
| Andrew Hirsch President & CEO, Director | Feb 13, 2026 | Award | +700,000 | – | – | 1,123,145 |
| Leonard Reyno Chief Medical Officer | Jan 16, 2026 | Sale | −10,000 | $2.22 | $22.20K | 156,382 |
| Kenneth Carl Anderson Director | Jan 2, 2026 | Award | +5,958 | $1.93 | $11.50K | 146,532 |
| Donna Roy Grogan Director | Jan 2, 2026 | Award | +7,513 | $1.93 | $14.50K | 66,142 |
| Paige Mahaney Chief Scientific Officer | Oct 28, 2025 | Tax withholding | −5,644 | $2.58 | $14.56K | 99,356 |
| Paige Mahaney Chief Scientific Officer | Oct 28, 2025 | Option exercise | +19,200 | – | – | 105,000 |
| Donna Roy Grogan Director | Oct 1, 2025 | Award | +6,740 | $2.15 | $14.49K | 58,629 |
| Kenneth Carl Anderson Director | Oct 1, 2025 | Award | +5,349 | $2.15 | $11.50K | 140,574 |
| Kendra Adams Chief Financial Officer | Sep 18, 2025 | Tax withholding | −2,775 | $3.32 | $9.21K | 162,342 |
| Kendra Adams Chief Financial Officer | Sep 18, 2025 | Option exercise | +6,250 | – | – | 165,117 |
| Leonard Reyno Chief Medical Officer | Jul 10, 2025 | Option exercise | +15,325 | – | – | 173,764 |
| Leonard Reyno Chief Medical Officer | Jul 10, 2025 | Tax withholding | −7,382 | $1.99 | $14.69K | 166,382 |
| Leonard Reyno Chief Medical Officer | Jul 10, 2025 | Tax withholding | −7,382 | $1.99 | $14.69K | 166,382 |
| Kenneth Carl Anderson Director | Jul 1, 2025 | Award | +7,616 | $1.51 | $11.50K | 135,225 |
| Donna Roy Grogan Director | Jul 1, 2025 | Award | +9,609 | $1.51 | $14.51K | 51,889 |
| Kenneth Carl Anderson Director | Apr 1, 2025 | Award | +7,841 | $1.44 | $11.29K | 127,609 |
| Donna Roy Grogan Director | Apr 1, 2025 | Award | +9,581 | $1.44 | $13.80K | 42,280 |
| Scott N. Boyle Chief Business Officer | Feb 18, 2025 | Sale(10b5-1 plan) | −669 | $3.15 | $2.11K | 107,805 |
| Andrew Hirsch President & CEO, Director | Feb 15, 2025 | Tax withholding | −9,370 | $3.18 | $29.80K | 423,145 |
| Scott N. Boyle Chief Business Officer | Feb 14, 2025 | Tax withholding | −2,368 | $3.18 | $7.53K | 108,474 |
| Scott N. Boyle Chief Business Officer | Feb 14, 2025 | Sale(10b5-1 plan) | −490 | $3.15 | $1.54K | 110,842 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
38.94%
47M shares short
Days to cover
15.1
At 3M shares a day
Change since last report
+9.0%
From 43M shares
Short volume, 20 days
54.5%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of C4 Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 32,532 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mark Mossler Officer | Aug 14, 2026 | 4,139 | $17.60K | Aug 14, 2026 | Restricted Stock |
| Jay Geldmacher Former REZI CEO | Aug 14, 2026 | 82,563 | $1.90M | Aug 14, 2026 | Restricted Stock |
| Mark Mossler Officer | Aug 13, 2026 | 15,000 | $61.07K | Aug 13, 2026 | Stock Option Exercise |
| Mark Mossler Officer | Aug 12, 2026 | 19,519 | $76.68K | Aug 12, 2026 | Stock Option Exercise |
| Mark Mossler Former Section 16 Officer | May 28, 2026 | 9,087 | $35.48K | May 27, 2026 | Grant under Issuer's 2020 Equity Incentive Plan |
| Jolie Siegel Officer | Mar 9, 2026 | 101,175 | $378.85K | Mar 9, 2026 | Stock Option Exercise |
| Malcolm Salter Director | Nov 18, 2024 | 13,000 | $54.53K | Nov 18, 2024 | STOCK OPTION EXERCISE |
| Malcolm Salter Director | Oct 18, 2024 | 13,000 | $83.32K | Oct 18, 2024 | STOCK OPTION EXERCISE |
| Malcolm Salter Director | Oct 11, 2024 | 8,561 | $46.06K | Oct 11, 2024 | STOCK OPTION EXERCISE |
See a number that looks wrong?